Acute graft versus host disease
MONDO:0020546A syndrome of immunologically mediated tissue damage that may occur following an allogeneic transplant, usually affecting the skin, liver, and GI tract. The onset is usually within one hundred days of transplantation or immunologic manipulation.
Also known as: GVHD, acute, acute graft vs. host disease, fulminant graft versus host disease, graft versus host disease, acute, acute GVHD
87 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
Poop pills or tubes: could fecal transplants tame deadly transplant complication?
Disease control Not yet recruitingThis study tests whether giving fecal microbiota (from a healthy donor) via a tube or scope into the gut can safely help children and young adults with severe intestinal graft-versus-host disease that hasn't improved with steroids. About 20 participants aged 3 months to 25 years …
Phase: PHASE1, PHASE2 • Sponsor: Bambino Gesù Hospital and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New model may predict and prevent deadly transplant complication
Disease control Not yet recruitingThis study tests whether giving the drug ruxolitinib early can prevent severe graft-versus-host disease (GvHD) in people getting a stem cell transplant. About 438 adults at intermediate-to-high risk, as identified by a special model called daGOAT, will be enrolled. The goal is to…
Phase: PHASE3 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Cord blood cells aim to tame deadly transplant complication
Disease control Not yet recruitingThis early-phase trial tests a new treatment called CK0802 for people with severe graft-versus-host disease (GVHD) that does not respond to steroids. GVHD is a serious complication after a bone marrow or stem cell transplant, where donor immune cells attack the patient's body. CK…
Phase: PHASE1, PHASE2 • Sponsor: Cellenkos, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Stem cell combo shows promise for deadly transplant complication
Disease control Not yet recruitingThis Phase 3 trial tests whether adding a stem cell therapy called remestemcel-L to the drug ruxolitinib can help adults with severe, steroid-resistant graft-versus-host disease (GVHD) after a bone marrow transplant. GVHD occurs when donor immune cells attack the patient's body. …
Phase: PHASE3 • Sponsor: Mesoblast, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Could vitamin c help protect the gut in transplant patients?
Disease control Not yet recruitingThis early-phase trial tests whether adding vitamin C to standard steroid treatment helps people with gastrointestinal graft-versus-host disease (GVHD), a serious complication after a donor stem cell transplant. About 35 participants aged 5 and older will receive vitamin C plus s…
Phase: EARLY_PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New drug combo aims to prevent dangerous transplant complication in rare blood cancer
Disease control Not yet recruitingThis study tests whether a new drug called gecacitinib, combined with standard anti-rejection medicine, can prevent a serious complication called graft-versus-host disease (GVHD) in people with myelofibrosis who receive a stem cell transplant. About 40 adults will take part. The …
Phase: NA • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New drug aims to stop deadly transplant complication
Disease control Not yet recruitingThis study tests a drug called ivarmacitinib to prevent acute graft-versus-host disease (aGVHD) in 32 people with blood cancers receiving a half-matched stem cell transplant. The goal is to see if the drug can lower the chance of severe GVHD and improve survival without long-term…
Phase: PHASE1, PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New hope for GVHD patients who fail standard therapy?
Disease control Not yet recruitingThis study tests a new drug called gecacitinib for people with acute graft-versus-host disease (GVHD) after a stem cell transplant. It is for those who did not get better or could not tolerate the usual second-line treatment. The trial will include 15 adults and aims to see if th…
Phase: PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Could probiotics from your donor fix gut problems after transplant?
Disease control Not yet recruitingThis early study tests whether probiotics made from the patient's own or their donor's gut bacteria can improve intestinal health in people with acute graft-versus-host disease (aGVHD) after a stem cell transplant. Ten participants over age 50 will take probiotic capsules and be …
Phase: NA • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New drug cocktail aims to tame transplant complication
Disease control Not yet recruitingThis phase 2 trial tests a combination of Gecacitinib (a pill) and a corticosteroid as the first treatment for grade II to IV acute graft-versus-host disease (aGVHD), a serious complication after a stem cell transplant. The study will enroll 25 adults who have recently received a…
Phase: PHASE2 • Sponsor: Bin Gu • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC